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Abstract: Tumor-transplanted rodents are primarily adopted to study cancer 
progression in vivo and the inhibitory potential of the immune system. Genetically 
engineered, cancer-prone mice, however, more closely mimic several features of 
human cancer. Inbred BALB/c female mice transgenic for the rat neu (Her-2/neu, 
ErbB-2) oncogene (BALB-neuT mice) constitute an intensively studied mammary 
cancer model. Key features of this model include that (1) each of their ten 
mammary glands develops an independent carcinoma that slowly progresses from 
microscopic lesions to invasive tumors; (2) multiple in situ carcinomas are 
accompanied by greater dissemination of neoplastic cells into the bone marrow; 
(3) lung metastases are evident in the later stages; (4) over-expression of the 
protein product of the transgenic neu oncogene in the newborn thymus induces the 
deletion of T cell clones reacting with high-affinity against it, while the step-wise 
progression of mammary lesions triggers negative regulation mechanisms that 
suppress antibody- and perforin-mediated immune surveillance mechanisms. 
Thus, boosts of innate immunity delay cancer progression and vaccines 
administered when only early microscopic lesions are present provide lifelong 
protection, whereas their efficacy tails off when they are administered to mice with 
more advanced lesions. Because this model mimics some of the most critical 
features of human disease, it has been successfully used to investigate a number 
of therapeutic agents, including the role of adaptor proteins (P130 cap), signal 
transducers (STAT3), phosphoinositide 3-kinase (PI3K), and oncogenic stress 
sensing kinases (MKK7) in neu-driven carcinogenesis, and assessment of the 
efficacy of brakitherapy in the control of mammary cancer. 
 
1. TRANSGENIC MOUSE MODELS 
OF CANCER. 
Experimental models are constructed to 
emphasize a few basic features of a complex 
situation. The deeper investigation of a 
particular set of functions they allow provides 
information from which the real situation can be 
inferred. Their responsibility is thus enhanced 
because their findings influence the rationale for 
fresh interventions. In vivo models of cancer 
provide information of importance for the 
implementation of therapies based on fresh 
concepts [1]. 
Tumor transplantation in syngeneic healthy, 
young rodents is a flexible way of studying a few 
features of neoplastic growth. Models of this 
kind have highlighted the central role of 
cytotoxic T lymphocytes (CTL) in tumor 
rejection [2]. This information was and is still of 
major importance since it provides the rationale 
for many ongoing clinical trials aimed at the 
activation of CTL for tumor therapy. However, 
these models confer no more than a snapshot that 
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distorts the tumor-host relationship owing to its 
unrealistic time dimension. Transplanted tumors 
usually grow and kill their hosts in a matter of 
few weeks and are thus an acute model of a 
relationship that in a cancer patient lasts several 
years. The brief time scale typical of 
transplantable tumors does not allow the 
observation of a few critical features of natural 
tumor growth, such as the selection of clones 
that no longer express the antigen targeted by the 
immune attack nor the histocompatibility 
glycoproteins required for T cell effector 
functions [3]. In addition, progressive adaptation 
of the immune system to the tumor antigens, the 
various kinds of tumor-borne 
immunosuppression and tumor and immune 
influences on the microenvironment never attain 
any significance in these fast models. By 
contrast, when the time scale of tumor-host 
relationship is longer, the reciprocal influences 
of the tumor and the immune system may shape 
the pace of cancer progression [4]. The limited 
life span of rodents as compared to humans does 
not permit to fully overcome the inappropriate 
time perspective [5]. Nevertheless, when the 
time is not anymore of few weeks but it is 
expanded to significant part of a rodent's natural 
lifespan, anti-tumor reaction mechanisms 
acquire a different, and often unforeseen 
importance [4, 6]. The recent availability of 
cancer prone genetically engineered mice 
(GEM) that naturally develop a tumor as a 
consequence of a defined gene alteration 
artificially inserted in their genome provides a 
challenging alternative to transplantable tumor 
models [7]. 
A defined genetic predestination to develop a 
tumor, tumor progression through defined 
stages, the natural occurrence of disseminated 
cells and metastasis, and the long-lasting 
interaction with the immune system are the 
appealing features of cancer prone GEM models 
[1]. 
The onset and progression of these tumors often 
mimic several features of their human 
equivalents. There are, however, pitfalls that 
may lead to distorted conclusions. A few GEM 
models are too artificial, since the gene 
alteration is foreign to the human setting. In 
others, the pathogenic alteration has no exact 
human equivalent. Because of the peculiarities 
of the transgene promoter, the genetic alteration 
of GEM mice may not follow the same 
developmental expression pattern as human 
cancer. Moreover, genetic aberrations may be 
overexpressed throughout a whole organ 
resulting in the parallel progression of several 
regions toward cancer. The timing of the first 
expression of the transgene affects the kind and 
intensity of the immune tolerance to the 
transgene protein product. When the transgene  
encodes a xenogeneic tumor antigen, the 
question whether the tolerance to it is 
comparable to that to autologous antigens of 
human tumors acquires crucial importance. 
Finally, a few GEM models are too cumbersome 
to be studied since the tumor arises only in a 
small percentage of mice or after an over-long 
latency [1]. 
 
2. MAMMARY CANCER PRONE 
BALB-neuT FEMALE MICE. 
GEM models mimic distinct features of human 
mammary cancer [7, 6, 8]. Because of the 
importance of the Her2/neu (ErbB-2) oncogene 
in human mammary carcinogenesis [9], and 
mostly thanks to the work of Leder and Muller, 
several lines of cancer-prone GEM overexpress 
the proto and the activated rat neu (r-neuT) 
oncogene in their mammary glands [10]. Those 
overexpressing the r-neu protooncogene closely 
reproduce the gene lesions that cause human 
mammary carcinoma in women, whereas those 
transgenic for the r-neuT have earlier tumors that 
grow aggressively, and thus better mimic the 
devastating progression, metastatizing ability, 
and lethality of human Her-2 mammary 
carcinoma [11].  
Of those expressing the r-neuT oncogene, inbred 
BALB/c mice expressing it under the 
transcriptional control of the mouse mammary 
tumor virus promoter long terminal repeats 
(MMTV-LTR promoter) (BALB-neuT mice) 
have been exploited in many experimental 
studies because of the consistency of the 
progression of their mammary lesions [1]. These 
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mice were generated by mating random-bred 
male mouse transgenic for Muller’s plasmid 
coding for the r-neuT oncogene [12] with a wild-
type BALB/c female. Back-intercrossing of their 
r-neuT+ male offspring for more than 50 
generations with wild-type BALB/c CR females 
[13] has provided the inbred BALB-neuT strain 
with a 100% mammary carcinoma penetrance. 
All females develop a mammary hyperplasia 
within the first month of life, and independent 
and progressively growing carcinomas are 
palpable in all their ten mammary glands within 
7 months [13, 14]. The r-neuT oncogene is 
mostly expressed in the mammary gland, and to 
a much lesser extent, and not always, in the 
salivary and Harderian glands [12, 15]. 
Mammary carcinogenesis outpaces that of the 
salivary glands in female BALB-neuT mice, 
whereas metastatizing salivary tumors are the 
prominent cause of death in the males [15, 16]. 
3. NATURAL HISTORY OF MAMMARY 
CANCER IN BALB-neuT FEMALE MICE. 
Pathological features. From the 4th week of life, 
cells in the not yet completely formed ducts of 
the mammary glands express the protein product 
of r-neuT oncogene, the r-p185neu protein. These 
r-p185neu+ cells proliferate and form side buds 
along most of the ducts of the mammary gland. 
Expanding side buds coalesce to give rise to 
atypical hyperplasia and then carcinoma in situ. 
These lesions grow to become invasive and 
palpable through the skin around the 19th week 
of life, and occupy the bulk of the subcutaneous 
fibroadipose tissue from the armpits down to the  
 
 
Fig. 1. Time course of mammary tumor development in 
BALB-neuT female mice. 
 
sites of the two sets of five mammary glands on 
each side of the groin (Fig. 1).  
Lung metastases are evident from the 30th week 
onwards. Whole mount, histological and 
immunohistochemical analyses are used to 
monitor tumor development [1]. 
Whole mount analyses from the 4th to the 10th 
week reveal the appearance of black spots with 
a roundish shape along the path of and within the 
ducts (Fig. 2A) that subsequently grow to form 
nodules very similar to the lesions of human 
carcinoma in situ (Fig. 2B) whose further 
expansion and clumping gives to masses that 
correspond to invasive carcinomas sometimes 
capable of occupying the whole of the gland and 
its subcutaneous tissue (Fig. 2C). 
Histological examination shows that from the 
4thto the 10th week, the small roundish spots 
displayed by the whole mount are side buds 
formed of neoplastic cells. 
 
 
 
Fig. 2. Whole mount preparations (A, B, C) and hematoxylin 
and eosin staining (D, E, F) of histological sections from 
BALB-neuT mammary glands at 10, 18 and 22 weeks of age. 
(Whole mount magnification x63, H&E x200). At 10 weeks 
of age, the whole mount preparations reveal small side buds 
along the mammary ducts (A). At 18 weeks, these have 
grown and coalesced to form dark nodules (B). At 22 weeks, 
they are very voluminous and occupy most of the mammary 
fat pad (C). Histological picture at 10 weeks showing side 
buds composed of ductal extraflexions lined with several, 
occasionally atypical epithelial layers, and still surrounded by 
myoepithelial cells and a basement membrane (D). At 18 
weeks, these buds have partly coalesced. They are larger and 
completely filled with neoplastic epithelial cells (carcinoma 
in situ) (E). At 22 weeks, they are even larger and formed of 
solid epithelial aggregates with a delicate interposed stroma. 
The masses are invading the surrounding fibroadipose tissue 
and are in contact with vessels and nerves (F). 
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Their basement membrane is still visible under a 
layer of myoepithelial cells (Fig. 2D). Around 
the 13th-14th week, some ducts, whose basement 
membrane is still distinguishable, are almost 
completely obliterated by neoplastic cells (Fig. 
2E) and the myoepithelial cells eventually 
disappear. From the 20thweek, the tumor begins 
to invade the surrounding fibroadipose tissues in 
the form of increasingly larger masses formed of 
clumps of cells separated by a delicate stromal 
tissue (Fig. 2F). 
Immunohistochemical analysis discloses 
overexpression of r-p185neu from the 4th week 
onwards by the neoplastic cells in all the lesions 
and the metastases (Fig. 3A, B, C). An assay 
with specific anti-PCNA antibodies shows that 
several tumor cells are proliferating (Fig. 3D, E, 
F). 
 
 
 
Fig. 3.Immunohistochemical staining of r-p185neu (A, B, C) 
and PCNA (Proliferative Cell Nuclear Antigen) (D, E, F) on 
sections from BALB-neuT mammary glands at 10, 18 and 22 
weeks of age (x 200). Immunohistochemical staining with 
anti r-p185neumonoclonal antibody shows constant r-p185neu 
overexpression by the neoplastic cells. Anti-PCNA staining 
reveals proliferative activity in numerous neoplastic cells. 
 
The combined histological and 
immunohistochemical picture shows that the 
number of stem cells (Sca1+, Musashi1+) is 
greater in the atypical hyperplasia and 
carcinoma in situ stages as opposed to the 
invasive carcinoma stage. The neoplastic cell 
proliferation index is very high in the early 
stages, especially during atypical hyperplasia, 
and the bordering stroma is copiously 
vascularized, whereas in the advanced stages a 
high index is only found in the more peripheral 
areas in contact with the stroma and on the tumor 
expansion front. 
The atypically hyperplastic ductules (weeks 4-
10 of age) are surrounded by many macrophages 
(CD11b+, CD68+/-), mainly in close contact with 
the numerous small vessels running in the 
delicate branches of the stroma. A few T CD4+ 
lymphocytes are also present. They remain 
confined to the outer borders of the growing in 
situ and invasive carcinomas, whereas numerous 
macrophages persist in the stroma. 
r-p185neu+ neoplastic cells begin to disseminate 
from the primary tumor during the 4th to 9th 
weeks of life, when it is in the atypical 
hyperplasia stage. They pass beyond the 
basement membrane, invade the stroma (Fig. 4), 
and enter the blood and lymph vessels. In 
addition, r-p185neu+ cells spread to the bone 
marrow. As already stated, therefore, 
dissemination begins in the initial stages of 
carcinoma growth when its intensity is greater 
than when the tumor is bigger. 
 
 
 
Fig. 4. Electron microscopy of a side bud from a 9-week-old 
BALB-neuT female mouse. A dysplastic luminal cell with its 
basal portion is passing through the interrupted basement 
membrane (black arrows), which is in direct contact with 
fundamental substance and collagen fibrils of the stroma. 
Above there is a myoepithelial cell (M) between the 
membrane (white arrows) and the ductal epithelial cells. 
 
Genomic hybridization has demonstrated that r-
p185neu+ cells disseminated in the bone marrow 
are rendered extremely dissimilar by their 
display of a variety of chromosome aberrations 
[17]. These aberrations, and those in the cells of 
the lung metastases, are not the same as those of 
the primary from which they must certainly be 
BALB-neuT female mice as a dynamic model of mammary cancer Animal Models of Diseases, 2011 
derived. Metastases, in other words, stem from 
genomically and chromosomally dissimilar cells 
that acquire further genetic alterations, partly 
influenced by their microenvironment, as their 
proliferation proceeds. The lungs are thus 
preferentially colonized by cells whose 
characteristics differ from those of the cells that 
invade the marrow. 
The observation of r-p185neu+ cells in the 
marrow is not an unequivocal indicator of the 
presence of frank metastases, nor is it yet clear 
whether they subsequently form lung 
metastases, though these are more likely built up 
by waves of r-p185neu+ cells brought in by the 
blood. In BALB-neuT females, in fact, clinically 
evident metastases are only found in the lungs. 
Here, neoplastic cells initially settle in 
capillaries and vessels before proliferating to 
form roundish intravascular nodules (Fig. 5B) 
that eventually invade the parenchyma (Fig. 5C). 
 
 
 
Fig. 5. Immunohistochemical staining of r-p185neu during 
metastatization of the lung by mammary neoplastic cells: (A) 
r-p185neu+ cell in a dilated lung capillary full of fibrin and 
activated endothelia; (B) dilated lung capillary with a string 
of three r-p185neu+ cells presumably brought in by successive 
waves of neoplastic dissemination; (C) proliferation of r-
p185neu+ cells to form solid aggregates with fibrin still 
interposed; (D) metastatic proliferation is mostly 
intravascular, with subsequent invasion of the parenchyma. 
 
Comparison with human breast tumors: 
differences and similarities. There are both 
morphological differences and similarities 
between this murine model and mammary 
carcinoma in women. This, in fact, usually 
appears in only one breast and in a single site, 
most frequently the external superior quadrant, 
whereas in BALB-neuT mice there is 
widespread proliferation along all the ducts of 
every breast, and the larger tumor masses are 
partly the result of coalescence of small nodules 
located in various portions of the ducts. As in the 
human tumor, on the other hand, the neoplastic 
cells are rendered dissimilar through their ability 
to express different molecules in function of the 
genic alteration they have acquired, and also 
through their crosstalk with the tumor 
microenvironment. 
All the neoplastic cells in the BALB-neuT 
model, however, overexpress r-p185neu+, 
whereas a substantial percentage of those in 
what are still classed as Her2+ human mammary 
tumor are actually Her2- (Fig. 6). Moreover, the 
over expression of r-neuT in the BALB-neuT 
model seems the only cause of the neoplastic 
transformation, whereas the human 
carcinogenesis is apparently due to 
accumulation of several genetic alterations.  
Neoplastic dissemination in the human 
bloodstream may be an early finding, and 
neoplastic cells are detected in the bone marrow 
of many breast tumor patients. This detection is 
indicative of a poor prognosis, whereas the 
presence of such cells in the blood has not yet 
been established as a sure sign of tumor 
progression. 
The BALB-neuT model permits investigation of 
both dissemination and metastatization, though 
the latter is confined to the lungs in the mouse, 
whereas many other human organs (bones, liver, 
adrenals, brain and meninges) are colonized. 
Dissemination, too, is a constant feature of the 
murine atypical hyperplasia and carcinoma in 
situ stages, whereas in humans it is probably less 
frequent, even if disseminated cells are found in 
the blood and bone marrow of some patients 
with very small and indeed still in situ tumors. 
 
4. IMMUNE MODULATION IN BALB-
neuT MICE. 
The expression of transgenic r-neuT is the only 
genetic difference between BALB-neuT and 
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wild-type BALB/c mice.  
Their immune systems can thus be directly 
compared to assess the consequences of both 
expression of r-p185neu and the progression of r-
p185neu+lesions. 
 
 
 
Fig. 6. Immunohistochemical staining of p185neu+ in 
mammary tumors from a BALB-neuT female mouse (A) and 
a human patient (B), and of VEGF and CD11b+ on an 18-
week BALB-neuT neoplastic lesion. p185neu is uniformly 
expressed in an all the neoplastic murine epithelial cells (A), 
whereas in the human setting positive and negative cells 
coexist even in cases classed as highly c-ErbB-2 positive 
(ErbB-2+++) (B). Despite their uniform r-p185neu+ expression, 
the murine tumor cells display markedly dissimilar 
production of angiogenic factors such as VEGF. Confocal 
microscopy shows that VEGF (green) is produced by 
macrophages (CD11b+ cells in red), and only by the 
neoplastic cells closest to the stroma and the macrophages 
themselves. 
 
Central tolerance to r-p185. The first critical 
change due to this expression is acquisition of a 
central tolerance to r-p185neu. In newborn 
BALB-neuT mice, transgenic r-p185neu is 
markedly and diffusely overexpressed by the 
thymic epithelium, whereas in adult mice it is 
mostly overexpressed mostly by mammary and 
salivary tissues. This has a dramatic impact on 
the repertoire of T cells that reach the periphery: 
CD8+ T cell clones that in wild-type BALB/c 
mice interact at high avidity with the dominant 
H-2Kd r-p185neu 63-71 epitope are missing in 
BALB-neuT mice. Immunization against r-
p185neu elicits high affinity CD8+ CTL in wild-
type BALB/c mice compared with only a 
marginal CTL response in BALB-neuT, whose 
immune response elicited by vaccines rests 
almost solely on activation of CD4+ T cells. 
Differences in thymic selection appear to be 
responsible for this split tolerance leading to 
selective deletion of CD8+ CTL [18, 19]. 
 
Expansion of immature myeloid cells. The 
lengthy stepwise progression of mammary 
lesions in female BALB-neuT mice is 
accompanied by expansion of Gr-1+ (Ly6G), 
Mac-1+ (CD11b), ER-MP12+ (CD31) immature 
myeloid cells in the peripheral blood and spleen, 
whose number increases marginally during the 
pre-neoplastic stages, then markedly when 
invasive carcinomas become palpable in the 
mammary pad and progress to large neoplastic 
masses. This relatively late expansion rests on 
the enhanced release by carcinoma cells of 
vascular endothelial growth factor and other 
factors, while its progressive inhibition of T cells 
results in their failure to respond to alloantigens 
and CD3 triggering [20]. 
 
Expansion of T regulatory (Treg) cells. The 
progression of r-neuT-driven carcinogenesis in 
the mammary glands of BALB-neuT female 
mice is also accompanied by a progressive 
expansion of CD4+, CD25+, Foxp3+, GITR+ Treg 
cells. Treg expansion is not evident or marginal 
until the appearance of hyperplasia and 
carcinomas in situ, but is rapid in both the spleen 
and the mammary lesions when these coalesce 
and progress to invasive carcinomas. This 
expansion can be seen as a natural response 
designed to physiologically dampen the 
autoimmune reaction elicited by anomalous 
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overexpression of r-p185neu by the expanding 
mammary lesions [21]. 
 
Perforin-dependent, NK and T cell surveillance. 
Despite the extreme oncogenicity of this model 
and the profound central tolerance to r-p185neu, 
immune surveillance mechanisms affect the 
onset of mammary carcinomas in BALB-neuT 
mice. Mammary lesions developing in BALB-
neuT mice as such and those in which the 
perforin gene has been knocked out (BALB-
neuT/pfp KO) display the same level of r-
p185neu expression. In the latter, however, 
carcinogenesis is accelerated. The latency time 
of the first mammary tumor is shorter, the 
progression from hyperplasia to invasive 
neoplasia is quicker, and the number of tumors 
per mouse is greater than in BALB-neuT mice. 
Both NK cells and CD8+ T cells are major 
populations that express the perforin effector 
molecule. Depletion of NK, but not CD8+ or 
CD4+ cells, speeds carcinoma onset [22, 23] 
suggesting that NK cells are the key perforin-
expressing effector cells that delay mammary 
carcinoma development in this model [22]. 
However, other experiments have revealed 
accelerated carcinoma progression in mice 
depleted of both CD8+ and CD4+ T cells [23]. 
 
The decline of immune surveillance. These data 
do much to indicate that cell-mediated immune 
surveillance impairs, but fails to fully prevent 
mammary carcinogenesis in these mice. 
Expression of the r-neuT oncogene into every 
mammary gland leads to continuous generation 
of tumor cells that should be kept at bay. This 
endless struggle between a tumor and an 
immune system eventually results in the 
expansion of regulatory mechanisms whose 
onset tips the scales against natural responses.  
IL-13 mediates the negative regulatory effect of 
type II, Vα14- TCR negative NKT cells [24]. 
When BALB-neuT female mice are treated with 
a soluble IL-13 inhibitor (sIL-13Ra2-Fc) from 
the stage of diffuse atypical hyperplasia until an 
invasive tumor is palpable, this IL-13 blockade 
improves immune surveillance and retards the 
appearance of mammary carcinomas. Even if the 
origin of IL-13 and its mechanisms of action 
were not yet defined in the BALB-neuT model, 
it was previously observed that IL13 released by 
type II NKT cells naturally primed by tumor 
growth may contribute to the suppression of 
immunosurveillance by inducing myeloid cells 
to enhance their suppressive activity by 
releasing TGF-β. The marginal expansion of 
immature myeloid cells during the early stages 
of mammary lesions may be enough to amplify 
the effects of this negative regulatory circuit 
[23]. 
The weight of regulatory circuits in the 
abrogation of natural immunosurveillance 
becomes even more evident following chronic 
Treg depletion started in these early stages [21]. 
BALB-neuT mice bearing mammary lesions of 
increasing size display marginal if any 
production of antibody and CD8+ T cell 
mediated citotoxicity against r-p185neu. 
However, when they receive repeated 
administrations of anti-CD25 monoclonal 
antibodies and undergo chronic depletion of 
Treg cells, a significant antibody and CTL 
mediated natural immunosurveillance against r-
p185neu+ tumors is unveiled. When r-neuT 
carcinogenesis takes place in the absence of Treg 
cell expansion, it is delayed by an unhampered 
natural response [21]. 
This presence of a natural antibody and CD8+ T 
cell mediated surveillance is apparently in 
conflict with the evidence of a central tolerance 
to r-p185neu acquired by BALB-neuT mice. The 
natural CTL response that follows Treg removal 
is due to low-avidity CD8+ CTL expressing an 
otherwise cryptic T cell repertoire. However, 
expansion of these CTL that have escaped 
thymic selection is normally concealed by Treg 
cell expansion in the periphery. Treg depletion 
allows them to expand and display a CTL 
response. Treg depletion also spurs spontaneous 
expansion of CD4+ T cells specific for r-p185neu 
[19]. 
 
Cytokine modulation of r-neuT carcinogenesis. 
Penetrance of r-neuT provides a major 
oncogenic signal. The features of mammary 
tumor progression, however, are markedly 
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modulated by cytokines in the tumor 
microenvironment. Microarray data show that a 
transcriptional signature associated with 
proinflammatory molecules can be defined 
during r-neuT-driven carcinogenesis [25]. When 
this signature is applied to a collection of human 
breast cancer data [26], it arranges them in 
function of different types or degrees of 
leukocyte infiltration.  
Proinflammatory activation in the mammary 
glands of BALB-neuT mice may thus reflect a 
general pattern of human breast cancer. 
Ingenuity analysis of genes associated with the 
tumor microenvironment identifies interferon 
(IFN) - as one of the four hub cytokine genes 
whose increased expression in this 
microenvironment is naturally associated with 
mammary cancer progression.  
These findings suggest that IFN-acts as an 
additional natural surveillance mechanism that 
impairs r-neuT carcinogenesis by restraining 
tumor-driven neoangiogenesis [25]. In IFN- 
KO BALB-neuT mice, in fact, progression is 
quicker and numerous, larger-than-normal 
caliber vessels covered with pericytes are 
present both inside and around the tumors. 
Tumor necrosis factor (TNF) is another hub 
cytokine gene whose expression increases 
during BALB-neuT mammary carcinogenesis 
[25]. 
While IFN-naturally inhibits r-neuT 
carcinogenesis, TNF plays a critical role in 
tumor promotion as shown by various mouse 
models [27, 28]. When BALB x C57BL/6 F1 r-
neuT mice are reconstituted with bone marrow 
cells from C57BL/6 mice KO for the TNF gene, 
r-neuT carcinogenesis is significantly impaired. 
In the absence of leukocyte-derived TNF, 
intratumoral vessels are disarranged, lack 
pericyte coverage and induce diffuse vascular 
hemorrhage and stromal necrosis [28]. 
 
5. EXAMPLES OF THE USE OF BALB-
neuT MICE IN TUMOR IMMUNOLOGY. 
The aggressiveness and consistency of r-neuT-
driven mammary carcinogenesis make BALB-
neuT female mice one of the models most 
frequently used to study immunity to 
autochthonous mammary cancer. The data 
outlined above show that overexpresson of the r-
neuT oncogene and the development of 
mammary carcinomas trigger multiple immune 
regulatory activities that affect the pace of 
cancer progression. As the tumor expands, 
suppressive regulatory circuits obscure the 
significance of cellular and antibody-mediated 
surveillance. Moreover, a delicate balance 
between the cytokines in the tumor 
microenvironment decides the pace of 
carcinogenesis, primarily by restraining or 
favoring tumor neoangiogenesis. 
The passage from each stage of the tumor-
immune system relationship to the next 
recapitulates several aspects of the dynamics of 
immune modulation in cancer patients. A cell 
and antibody-mediated reaction to tumor-
overexpressed Her-2 is evident in women with 
mammary cancer [29] while rampant 
immunesuppression is a common feature of 
patients with advanced tumors [30]. 
The interactions with immune mechanisms that 
shape the progression of mammary cancer make 
BALB-neuT mice an appealing model for 
assessment of the potential and limits of immune 
interventions designed to modify the tumor 
microenvironment, boost of host innate 
immunity, and find ways of overcoming immune 
tolerance to tumor associated antigens. 
 
Systemic IL-12. Modulation of the innate 
immunity of BALB-neuT mice by prolonged 
administration of IL-12 (5 daily intraperitoneal 
injections of 100 ng, one week on, 3 weeks off) 
significantly delays mammary carcinogenesis 
and reduces tumor multiplicity mainly by 
inhibiting tumor-induced angiogenesis [11]. 
This antiangiogenic effect is stronger on the 
fragile capillaries that accompany the shift from 
the preneoplastic to the neoplastic condition, 
whereas the mature and differentiated vessels of 
the more advanced neoplastic lesions are less 
susceptible [31]. It is primarily the result of IL-
12's ability to induce high and sustained serum 
levels of IFN-, a goal that can be reached by 
administering low doses of IL-12 [32]. 
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Local and systemic CpG. Modulation of the 
tumor microenvironment with Toll-like receptor 
(TLR) ligands such as non-methylated-CpG 
oligodeoxynucleotides (CpG-ODN) induces a 
strong local reaction that persistently impair 
mammary carcinogenesis. Starting when in situ 
carcinomas were scattered over all the mammary 
glands of BALB-neuT mice, CpG-ODN 1826 
were injected in the stroma of the fourth left 
mammary gland six times at four week intervals. 
At one year of age, 67% of these glands were 
tumor-free, and an impressive reactive infiltrate 
of macrophages, CD4+, CD8+, and B220+ cells 
formed a carpet around the precancerous lesions. 
This treatment both delayed the onset of 
carcinomas in the injected glands, and also 
extended the latency of tumors in glands both 
close and far from the injection site [33]. In 
effect, a major drawback on the use of CpG is 
that intratumoral injection is not always 
possible. To target GpG-ODN to a tumor site 
anywhere within the body a hybrid between a 
monoclonal antibody directed against r-p185neu 
(7.16.4 from D. M. Greene) [34] and CpG-ODN 
has been produced. Its intravenous injection 
leads mice to rejection of a challenge of 
syngeneic r-p185neu+ tumors on the part of 30% 
of BALB-neuT mice. Combination of GpG-
ODN with the removal of Treg cells leads all 
BALB-neuT mice to reject the tumor challenge 
and acquire a tumor-specific immune response 
[35]. 
 
Zoledronic acid (ZA). ZA is the most potent 
nitrogen-containing bisphosphonate. Lifelong 
intravenous administration of clinically 
compatible doses of ZA to BALB-neuT mice 
once a week for 4 consecutive weeks, repeated 
after 3 weeks of rest, induces a significant 
increase in tumor-free and overall survival by 
modifying the tumor microenvironment. The 
tumor stroma of ZA-treated mice did not show 
significant differences in the number of 
infiltrating CD4+ and CD8+ T lymphocytes, B 
lymphocytes, Treg cells, granulocytes and 
gamma-delta T cells. By contrast, CD11b+ 
macrophages associated with the mammary 
lesions were strongly reduced and displayed a 
dramatically reverted polarization from M2 to 
M1 phenotype. They no longer produce IL-10 
and become strongly positive for IFN-. This re-
polarization of macrophages greatly influences 
the pace of r-neuT carcinogenesis since it is 
associated with both a reduced production of 
VEGF and a markedly restrained neo-
vascularization of mammary lesions [36]. 
 
Oral human lactoferrin. Lactoferrin is an iron-
binding glycoprotein present in milk, tears, nasal 
exudates, saliva, bronchial mucus, 
gastrointestinal fluids, cervicovaginal mucus 
and seminal fluid. It is also secreted by 
neutrophils and present at high levels at sites of 
bacterial infection. The recombinant human 
lactoferrin produced in Aspergillusniger 
(Talactoferrin, TLF) differs from native human 
lactoferrin only in the nature of its glycosylation. 
When BALB-neuT mice received TLF (3 
mg/m2) administered orally by gavage once a 
day, 5 days per week, 3 weeks on and 1 week 
rest until mammary tumors were evident, their 
progression was markedly delayed. The disease-
free survival was extended and tumor 
multiplicity was reduced [37]. 
 
Anti r-p185neu vaccines. The consistent stepwise 
progression of mammary cancer in BALB-neuT 
mice provides a convenient model with which to 
weigh the preventive and therapeutic efficacy of 
anti Her-2 vaccines. Straightforward assessment 
of the potential and limits of the immunity 
induced is obtained by immunizing mice with 
mammary lesions of progressive size.  
a. DNA vaccines. Injection of DNA plasmids 
coding for portions of r-p185neu [38], their 
combination with adjuvants of different kinds 
[39, 40, 41], and the injection of plasmids 
encoding fusion proteins consisting of a portion 
of human p185neu fused to the extracellular 
domain of CTLA-4 to better target their delivery 
to antigen-presenting cells [42] elicit a 
significant protection against the onset of 
mammary lesions. Stronger protection is 
obtained when injection of plasmids encoding 
for the extracellular and transmembrane 
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domains of r-p185neu is followed by 
intramuscular electroporation [43, 44]. Their 
combination with weekly administration of IL-
12 enables vaccination to provide protection at 
late points in time when vaccine electroporation 
alone is ineffective [45]. Through 
electroporation of plasmids encoding 
progressively smaller portions of r-p185neu the 
smaller epitopes still able to elicit a marked 
protection are defined [46]. Electroporation at 
ten-week intervals of plasmids coding for a 
chimeric rat-human p185neu molecule provides 
lifelong protection in more than 50% of BALB-
neuT mice [47]. The protection afforded by 
plasmid electroporation is enhanced by its 
combination with CpG-ODN SM360320, an 
agonist of TLR 7 [48] or a new CpG-ODN 
antagonist of TLR 9 [49].  
b. Cell vaccines. A significant and persistent 
protection is also afforded by cellular [50, 51] 
and DNA [52] vaccines combining r-p185neu, an 
alloantigen, with IL-12. A strong protection is 
also elicited by vaccination with dendritic cells 
engineered to express a portion of r-p185neu [53]. 
Comparison of the protection afforded by 
vaccination with murine NIH3T3 cells 
engineered to express rat or human p185neu, or 
human EGFR, ErbB-3 and ErbB-4 showed that 
the best protection was induced by cells 
expressing r-p185neu. Lower protection was 
elicited by NIH3T3 expressing human p185neu 
and the three ErbB receptors [54]. 
c. Peptides. Immunization with conformational 
peptide constructs that mimic regions of the 
dimerization loop of the r-p185neu constructs 
(peptide 266-296; 298-333; 315-333) elicits 
high-affinity antibodies that inhibit r-p185neu 
dimerization and its signaling pathways, mediate 
antibody-dependent cellular cytotoxicity and 
reduce carcinoma onset [55]. Another 
conformational peptide (597–626) constructed 
to include the native disulfide bonds to more 
closely mimic the native structure of r-p185neu 
inhibits carcinoma onset more efficiently than its 
linear counterpart [56]. Significant preventive 
immunity is also elicited by repeated 
vaccinations with a synthetic peptide of r-
p185neu in combination with the Toll-like 
receptor antagonist CpG-ODN1826. CTL 
response and antitumor effects become evident 
when the function of Treg cells is blocked [57]. 
d. Viruses. Virus-like particles containing 
extracellular and transmembrane domain of 
human r-p185neu [58], recombinant vaccinia 
virus encoding full-length human p185neu[59], or 
vaccination with adenovirus encoding wild-type 
[60, 61] or codon usage-optimized [62] portions 
of r-p185neu are other convenient ways of 
breaking tolerance and inducing a persistent 
immune response. 
The protection afforded by these vaccines 
usually stems from the induction of  anti-r-
p185neu antibodies that inhibit tumor progression 
by blocking the signals delivered by r-p185neu 
[55, 56, 60, 63-65] or recruiting antibody-
dependent cellular toxicities [44, 49, 55, 56]. 
They occasionally elicit a CTL response 
probably due to their ability to trigger the low-
avidity CD8+ T cells that escape central 
tolerance [49, 57, 58, 61]. This rare response is 
markedly enhanced by concomitant removal of 
Treg cells [19, 35, 57]. 
 
Whole transcriptome characterization of the 
effect of anti-r-p185neu vaccines. The first whole 
transcriptome characterization of BALB-neuT 
mammary cancer was published in 2004 [63] It 
showed that a combined DNA and cell vaccine 
persistently inhibited breast cancer lesions. The 
further observation of a strong concordance 
between whole-mount morphologic findings and 
gene expression patterns indicated that the 
reaction elicited by anti r-p185neu vaccines elicit 
a reaction halts the progression of preneoplastic 
lesions, coupled with the reversion of mammary 
lesions to the stage when vaccination began (see 
below). Attention was also drawn to the 
presence of a group of genes generically 
pertinent to the humoral response and encoding 
antibody-related genes only in the vaccinated 
mice. This paper was soon followed by another 
[66] that reported prevention of multifocal 
mammary carcinogenesis by means of a vaccine 
combining IL-12 and allogeneic p185neu+ 
mammary carcinoma cells. It was also found that 
transcription profiling of mammary tissue from 
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vaccinated mice displayed a gene expression 
signature different from that of untreated, tumor-
bearing mice, but similar to that of 
normal/hyperplastic mammary glands. The 
tumors which develop in the r-neuT mice have a 
basal-like signature, in agreement with human 
data. The BALB-neuT model thus also mimics 
human Her-2-induced tumorigenesis in its 
similarity to basal-like tumors. Subsequent work 
[67] showed that combination of the two 
microarray sets derived from the two 
immunization protocols applied in two 
laboratories to the same breast cancer model 
revealed their clear correlations between the 
increase of tumor mass and the transcription 
profiling. It was also clear that both protocols 
induced a strong, polyclonal antibody response 
and halted tumor growth at a condition very 
similar to that at which the vaccination began. 
Differences in the expression profiles were 
mainly related to the levels of a few chemokines 
and T-cell-specific genes that may be in some 
way correlated with the efficacy of the 
vaccination. Furthermore, combination of the 
expression data with the protection results 
indicated that chronic vaccination is needed to 
maintain an active IFNγ-mediated response in 
the mammary gland. 
 
An anti-angiomotin vaccine. Electroporation of 
BALB-neuT mice with a DNA vaccine targeting 
the angiostatin receptor angiomotin (Amot) 
expressed in tumor and placental endothelium 
breaks tolerance and elicts antibodies that detect 
Amot on the surface of endothelial cells. While 
the immune response elicited has no significant 
effect on the progression of mammary 
carcinogenesis progression, significant 
alterations were evident in the morphology of 
the vessels associated with it. Combination of 
anti r-p185neu and anti-Amot vaccination 
provides stronger and more persistent 
prevention, More than 80% of BALB-neuT mice 
remained cancer-free for over 70 weeks [68]. 
 
Identification of new oncoantigens. Microarray 
data extensively monitor gene expression in 
human tumors and their murine counterparts, 
and hence can be used to identify new tumor-
associated-antigens for targeting by vaccines 
whose efficacy and safety can easily be 
evaluated in mice. A meta-analysis of the human 
and murine data provided the first time rough 
version of a procedure for identification of new 
tumor antigens by tagging murine tumor-
associated genes in function of the correlation 
between their expression and the increase in 
tumor mass, and then selecting those with a 
limited expression in normal human tissues [69]. 
Subsequent refinement of this approach [70, 71] 
resulted in two major changes: 
I) the amount of human breast cancer samples 
used to associate with the human disease the 
“tumor-associated genes” tagged in the BALB-
neuT model was massively enlarged; 
II) The behavior of the putative TA in human 
pathological and normal tissue was evaluated 
with a reference set of genes. Specifically a well-
known set of oncoantigens, i.e. antigens with a 
causal role in the promotion of tumor 
progression [6] was used. The ErbB family was 
employed as the benchmark for identification of 
new oncoantigenes, i.e. genes characterized by 
an expression profile comparable to or higher 
than that of ErbB family members in human 
breast cancer, and comparable to or lower than 
that observed of these members in normal 
human tissues. This approach identified a set of 
interesting candidates as new oncoantigens [70]. 
Transcription profiling of BALB-neuT mice has 
thus indicated the enormous amount of 
knowledge that can be retrieved by combination 
of well addressed biological questions and a very 
robust cancer model. 
 
6. EXAMPLES OF THE USE OF BALB-
neuT MICE IN ONCOLOGY 
A model acquires special significance when it is 
exploited by several laboratories to study 
distinct issues since integration of their datasets 
may provide a comprehensive view of the 
problem studied. Progressive definition of the in 
vivo features of tumor growth and those of the 
tumor-host immune relationship is the subject of 
studies designed to elucidate a few molecular 
features of Her-2 carcinogenesis. 
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Role of p130Cas. p130Cas is an adaptor 
molecule that regulates cell motility and 
invasion. It is overexpressed in a significant 
subset of human breast cancers, while 
association of its high levels with Her-2 
expression correlates with elevated proliferation. 
Transgenic mice overexpressing p130Cas in 
their mammary glands display extensive 
mammary epithelial hyperplasia during 
development and pregnancy, and delayed 
involution at the end of lactation. When they are 
crossed with BALB-neuT mice, double-
transgenic mice develop mammary tumors with 
a shorter latency than their wild-type r-neuT+ 
littermates. Western blot analysis of from 
primary cultures of cells from the tumors of 
double transgenic mice showed that p130Cas is 
highly overexpressed. Moreover, they displayed 
increased levels of tyrosine-phosphorylated 
proteins as well as active Src, whereas Erk1/2 
MAPK activities were unaffected. 
Phosphorylation of PTEN, Akt, and Gsk3-h was 
also much more induced [72]. To further prove 
the weight of p130Cas in the growth of r-neuT-
dependent spontaneous tumors, 12-week-old 
BALB-neuT mice displaying many mammary in 
situ carcinomas received 50 µl of p130Cas-
stabilized siRNAs in their 4th-gland ductules by 
intranipple injection. Whole-mount analysis 6 
weeks later showed that these glands developed 
significantly less severe lesions than those 
glands injected with control siRNAs. Western 
blot analysis of mammary gland extracts 
revealed that p130Cas was effectively knocked 
down and its down-regulation correlated with 
decreased Fak phosphorylation, Src and Akt 
activation, and reduced level of cyclin D1. These 
data indicate that p130Cas contributes to the 
accelerated ErbB-2-induced transformation, 
while its silencing during the progression of 
spontaneous ErbB-2 tumors impairs their growth 
[73]. 
 
Role of Signal transducer and activator of 
transcription 3 factor (STAT3). STAT3 is 
constitutively active in a high percentage of 
human tumors, including mammary 
adenocarcinomas, and its participation in Her-2 
oncogene signaling has been reported. When 
BALB-neuT mice were crossed with mice in 
which Stat3 was selectively deleted in the 
mammary epithelium, the same rate of 
mammary carcinoma growth and progression 
was displayed by Stat3-sufficient and Stat3-
deficient mammary glands. This suggests that 
Stat3 is not required for r-neuT-driven 
mammary tumorigenesis [74]. In the opposite 
situation, to assess the potential cooperation of 
an activated Stat3 with the r-neuT oncogene in 
mammary tumorigenesis, BALB-neuT mice 
were intercrossed with mice carrying a mutant, 
constitutively active Stat3C allele that replaces 
the endogenous wild-type allele. r-neuT 
Stat3C/WT mice developed tumors significantly 
earlier than their r-neuT/Stat3WT/WT control 
littermates. At 12 weeks of age, r-
neuT/Stat3C/WT mice already presented invasive 
carcinomas, with tumor cells grouped in solid 
masses and small aggregates invading the 
surrounding fibroadipose tissue, whereas only 
atypical hyperplastic foci and few in situ 
carcinomas were detected in the r-
neuT/Stat3WT/WT mice. These earlier tumors 
display a proliferation rate similar to that of r-
neuT Stat3WT/WT mice, but an appreciably 
reduced apoptosis. 
Stat3C fails to induce tumorigenesis on its own. 
It does, however, cooperate with the r-neuT 
oncogene by providing protection from 
apoptosis, a probable source of the earlier tumor 
onset, and promoting tumor aggressiveness and 
metastatic potential [75]. 
 
Role of phosphoinositide 3-kinase (PI3K). The 
PI3K pathway controls metabolism and cell 
growth. It is also involved in the Her-2-mediated 
proliferation of mammary gland epithelium, 
while mutations of the PIK3K gene are 
associated with ErbB-2 amplification. Class IA 
PI3Ks are heterodimers composed of a catalytic 
subunit encoded by the PIK3CA, PIK3CB, and 
PIK3CD genes, and an Src homology 2, 
domain–containing adaptor protein. To study the 
importance of the link between PI3KCB and 
ErbB-2 signaling, BALB-neuT mice were 
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intercrossed with mutant mice expressing a 
catalytically inactive PIK3CB (PIK3CBK805R 
mice). While the mammary lesions of r-
neuT/PIK3CBK805R mice display the same 
expression of r-p185neu, r-neuT/PIK3CBK805R 
mice displayed a strong reduction of the early 
atypical hyperplasia. At later stages, foci of 
transformation, the numbers of proliferating 
cells, the tumor multiplicity and the rate of tumor 
growth were still reduced. When the cells of 
autochthonous tumors are cultured in vitro, those 
from r-neuT/PIK3CBK805R tumors grow 
significantly slower than controls. Taken as a 
whole, these data suggest that restrained growth 
of  r-neuT tumors is intrinsic to the function of 
the PIK3K gene in the mammary gland 
epithelium [76]. 
 
Role of MKK7 kinases. Oncogenic stress 
activates the DNA damage response and the key 
tumor suppressor p53, which prohibits tumor 
growth. To assess the function of stress kinase 
signaling in epithelial tumorigenesis Map2K7 
was deleted in mammary epithelial cells. These 
mice (Map2K7Dmamm mice) were crossed with 
BALB-neuT mice. r-neuT/Map2K7Dmamm mice 
displayed a much earlier onset of mammary 
carcinomas. Moreover their overall survival was 
markedly reduced compared to control 
littermates. At 16 weeks of age, their mammary 
glands of r-neuT/Map2K7Dmamm harbored many 
carcinomas compared with only a few lesions in 
the controls. These results show that deletion of 
Map2K7 facilitates r-neuT driven 
carcinogenesis, whereas MKK7 is a potent 
mammary tumor suppressor [77]. 
 
Therapeutic effect of brachytherapy. 
Brachytherapy (from the Greek "brachys" = 
short) refers to the use of radionuclides within or 
close to a tumor: a pre-targeted tissue may 
permit selective accumulation of radionuclides 
administered systemically. AvidinOX is an 
avidin derivative that resides more persistently 
than avidin within normal and neoplastic tissues, 
with a tissue half-life is about two weeks. Its 
intranipple injection into the ductules of a 
BALB-neuT mammary gland results in very 
efficient capture of 90Y-biotinDOTA injected 
intravenously 48 hours later, and leads to the 
eradication of multifocal cancer lesions [78]. 
 
7. CONCLUSIONS 
The data summarized above show how a 
dynamic and consistent model of cancer can be 
exploited to study many features of Her-2 
carcinogenesis. 
The picture emerging from immunological 
studies is that even an aggressive mammary 
carcinogenesis such as that driven by 
overexpression of an activated transgenic 
oncogene is modulated by the microenvironment 
and natural immune surveillance. Maneuvers 
designed to change a few features of the 
microenvironment have major consequences on 
cancer progression. In the BALB-neuT mouse 
model, modulation of the early stages of tumor-
driven neoangiogenesis critically affects the 
pace of mammary carcinogenesis. Vaccines of 
different kinds provide significant protection 
against the onset of cancer. Repeated boosting of 
a vaccine first administered prior to the 
appearance of a tumor provides lifelong 
protection. Interventions that temporarily 
remove suppressor activities may dramatically 
enhance the ability of a vaccine to cure 
established cancers. 
Lastly, the study of slowly progressing 
mammary cancer shows the direct and indirect 
importance of anti-p185neu antibodies, whose 
role is insignificant in models of fast growing 
transplantable tumors where CTL provides the 
only therapeutic mechanism. The data from 
models of autochthonous cancer may serve to 
change the way antitumor vaccines to be 
designed, and integrate the induction of 
antibodies in the immune response among the 
immune mechanisms to be activated [71, 79]. 
The consistent progression of mammary lesions 
of BALB-neuT mice is also exploited to 
elucidate genes and gene products for their 
interactions that may modulate ErbB-2-driven 
carcinogenesis, and exploit new strategy of 
novel therapeutics.  
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